Maverick Capital Ltd. Has $3.46 Million Stake in Elanco Animal Health Incorporated $ELAN

Maverick Capital Ltd. raised its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 35.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 144,457 shares of the company’s stock after acquiring an additional 37,864 shares during the quarter. Maverick Capital Ltd.’s holdings in Elanco Animal Health were worth $3,457,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. NewEdge Advisors LLC grew its holdings in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the last quarter. Root Financial Partners LLC boosted its position in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new stake in shares of Elanco Animal Health during the fourth quarter worth $41,000. Torren Management LLC bought a new stake in shares of Elanco Animal Health during the fourth quarter worth $46,000. Finally, Bessemer Group Inc. increased its holdings in shares of Elanco Animal Health by 33.2% during the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after buying an additional 525 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $25.48 on Tuesday. Elanco Animal Health Incorporated has a twelve month low of $13.39 and a twelve month high of $27.72. The firm has a fifty day simple moving average of $24.12 and a 200 day simple moving average of $23.99. The company has a market capitalization of $12.73 billion, a PE ratio of -50.97, a P/E/G ratio of 1.63 and a beta of 1.68. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter in the previous year, the business earned $0.37 earnings per share. Elanco Animal Health’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on ELAN. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. TD Cowen increased their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Morgan Stanley lifted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. Finally, JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.73.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 4,971 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the transaction, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is owned by corporate insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.